Guillain-Barré syndrome (GBS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Guillain-Barré syndrome (GBS)

Guillain-Barré syndrome is an autoimmune disorder that affects the nerves. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. Guillain-Barré syndrome (GBS) also known as -

• Acute infectious polyneuritis,

• Acute inflammatory polyneuropathy,

• Fisher syndrome

• GBS

• Guillain-Barre syndrome

• Landry-Guillain-Barre syndrome

Thelansis Epidemiology study suggest prevalence of GBS is estimated to be 6 to 40 cases per 1 million people. The occurrence of the different types of Guillain-Barré syndrome varies across regions. AIDP is the most common type in North America and Europe, accounting for approximately 90 percent of cases of Guillain-Barré syndrome in those regions. AMAN and AMSAN together account for 30 to 50 percent of cases in Asian countries and Latin America but only 3 to 5 percent of cases in North America and Europe.

Competitive landscape of GBS includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

Read more: Guillain-Barré syndrome (GBS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

KOLs insights of GBS across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

GBS Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

S. No        Asset        Company           Stage

1        ANX005        Annexon, Inc.        Phase 3

2        Eculizumab        Alexion Pharmaceuticals          Phase 3

3        CK0801        Cellenkos, Inc.        Phase 1

4        GB-0998        Japan Blood Products Organization        Phase 3

5        Imlifidase        Hansa Biopharma AB        Phase 2

6        NPB-01        Nihon Pharmaceutical Co., Ltd        Phase 3